Clinical Study
Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study
| | Baseline (IQD) | After 8 weeks of treatment (IQD) | Wilcoxon signed ranks Test |
| Median frequency/day | 11.7 (9.3–13.4) | 9.5 (6.9–10.9) | | Median volume voided/void | 121.9 (103.1–152.9) | 155.3 (103.1–198.2) | | Median incontinence episodes/day | 1.3 (0.0–2.7) | 0.2 (0.0–1.7) | | Median no. pads used/day | 2.0 (0.0–3.4) | 1.0 (0.0–2.0) | | Median severity of urine loss (0–3; daily added score) | 1.2 (0.0–5.0) | 0.3 (0.0–2.8) | | Median degree of urgency prior to voiding (0–3; daily added score) | 36.3 (28.8–47.3) | 23.7 (18.0–31.0) | |
|
|